INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 70 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $242,088 | -14.6% | 8,800 | -5.4% | 0.10% | -22.1% |
| Q4 2023 | $283,557 | -92.0% | 9,300 | -91.7% | 0.12% | -82.4% |
| Q3 2023 | $3,551,938 | -13.6% | 112,332 | +11.4% | 0.69% | +0.9% |
| Q2 2023 | $4,111,929 | +4348.7% | 100,832 | +3965.8% | 0.69% | +3711.1% |
| Q1 2023 | $92,430 | -96.3% | 2,480 | -96.5% | 0.02% | -96.3% |
| Q4 2022 | $2,490,448 | -37.6% | 71,380 | 0.0% | 0.48% | -38.8% |
| Q3 2022 | $3,994,000 | +8.1% | 71,380 | 0.0% | 0.79% | +5.6% |
| Q2 2022 | $3,695,000 | -29.6% | 71,380 | -1.1% | 0.74% | -20.0% |
| Q1 2022 | $5,247,000 | -38.0% | 72,200 | +0.8% | 0.93% | -26.9% |
| Q4 2021 | $8,466,000 | +0.3% | 71,600 | +13.8% | 1.27% | +81.5% |
| Q3 2021 | $8,438,000 | +263.7% | 62,900 | -48.9% | 0.70% | +207.9% |
| Q3 2016 | $2,320,000 | +58.3% | 123,159 | 0.0% | 0.23% | +51.0% |
| Q2 2016 | $1,466,000 | – | 123,159 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 744,160 | $54,078,000 | 5.79% |
| Discovery Value Fund | 986,173 | $71,665,000 | 5.28% |
| Ally Bridge Group (NY) LLC | 60,000 | $4,360,000 | 3.23% |
| MPM BioImpact LLC | 159,409 | $11,584,000 | 3.11% |
| ARK Investment Management | 8,981,029 | $652,651,000 | 2.72% |
| Elmwood Wealth Management, Inc. | 67,599 | $4,912,000 | 2.52% |
| Nikko Asset Management Americas, Inc. | 2,872,269 | $192,442,000 | 1.41% |
| Frazier Life Sciences Management, L.P. | 203,684 | $14,802,000 | 1.26% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $8,098,000 | 1.22% |
| Merlin Capital, Inc | 11,575 | $841,000 | 1.11% |